Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Which European healthcare stocks are most attractive right now? We asked Seeking Alpha analysts Edmund Ingham, Wolf Report ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment returns to a record 8 billion euros ($8.66 billion) in 2024, it said on ...

Novo Nordisk A/S (NVO)'s share was trading at $ ... These drugs have transformed Novo into a healthcare powerhouse, with Ozempic alone generating $16.7 billion in 2024, reflecting a 17.6% increase ...

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Novo Nordisk (NVO) is not a stock that is constantly staring at me from my screen, hoping I will get its attention. I like the Dow 30 and maybe another 20 stocks. I will consider just about ...

Novo Holdings is a life sciences investment powerhouse that manages assets for the Novo Nordisk Foundation, one of the world's biggest philanthropic bodies. "2024 was a very strong year for Novo ...